SCHEMBL4096459

SCHEMBL4096459

COC(=O)c1sc(-c2cccc(Cl)c2)cc1N

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.78
KDM4E B2RXH2 7/20 0.78
RAB9A P51151 5/20 0.78
NPC1 O15118 4/20 0.78
CASP3 P42574 2/20 0.78
SENP8 Q96LD8 2/20 0.78
SENP7 Q9BQF6 2/20 0.78
SENP6 Q9GZR1 2/20 0.78
IKBKB O14920 5/20 0.65
ALDH1A1 P00352 7/20 0.56
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
HPGD P15428 4/20 0.56
HSD17B10 Q99714 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
POLB P06746 1/20 0.55
RXFP1 Q9HBX9 2/20 0.54
LMNA P02545 1/20 0.54
PKM P14618 1/20 0.54
GAA P10253 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6612856 0.95 MAPT (0.70) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL6628323 0.95 MAPT (0.70) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL1531346 0.87 MAPT (1.00) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL431794 0.87 MAPT (0.74) MAPTKDM4ERAB9ANPC1CASP3
Hydrochloric Acid SCHEMBL8864118 0.86 MAPT (0.72) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL4081426 0.85 MAPT (0.67) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL1405912 0.84 IKBKB (0.78) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL4086036 0.83 IKBKB (0.60) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL4086753 0.83 IKBKB (0.75) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL10070140 0.81 MAPT (0.78) MAPTKDM4ERAB9ANPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 WO disclosed
US-20090181962-A1 Substituted thiophene compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2009-07-16 US disclosed
US-7358376-B2 Substituted Thiophene compounds ASTRAZENECA AB (SE) 2008-04-15 US disclosed
US-6492364-B1 Triazolo and derivatives as chemokine inhibitors TORAY INDUSTRIES, INC. (JP) 2002-12-10 US disclosed
EP-1261600-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 AstraZeneca AB (SE) 2002-12-04 EP disclosed
US-6441019-B2 E. G., 6-(3-CHLOROPHENYL)-1,4-DIHYDRO-4,4-DIMETHYL-2H-THIENO-(2,3-D)(1,3) OXAZINE-2-ONE; AGONISTS AND ANTAGONISTS OF THE PROGESTERONE RECEPTOR; INDUCING CONTRACEPTION AND TREATING OR PREVENTING BENIGN OR MALIGNANT NEOPLASTIC DISEASES WYETH 2002-08-27 US disclosed
CN-1349538-A Cyclic carbamate and cyclic amide derivatives AMERICAN HOME PROD (US) 2002-05-15 CN disclosed
US-6380178-B1 CONTRACEPTION WHICH COMPRISES ADMINISTERING TO A FEMALE OF FOR 28 CONSECUTIVE DAYS: FIRST PHASE OF FROM 14 TO 24 DAILY DOSAGE UNITS OF A PROGESTATIONAL AGENT LEVONORGESTREL; SECOND PHASE OF FROM 1 TO 11 DAILY DOSAGE UNITS OF ANTIPROGESTIN COMPOUND AMERICAN HOME PRODUCTS CORPORATION 2002-04-30 US disclosed
EP-1185535-A1 CYCLOCARBAMATE AND CYCLIC AMIDE DERIVATIVES American Home Products Corporation (US) 2002-03-13 EP disclosed
US-20020002173-A1 Cyclocarbamate and cyclic amide derivatives LIGAND PHARMACEUTICALS INCORPORATED 2002-01-03 US disclosed
US-6306851-B1 ADMINISTERING TO A MAMMAL A COMPOUND FOR BENIGN OR MALIGNANT NEOPLASTIC DISEASE IS SELECTED FROM UTERINE MYOMETRIAL FIBROIDS, ENDOMETRIOSIS, BENIGN PROSTATIC HYPERTROPHY; AMERICAN HOME PRODUCTS CORPORATION 2001-10-23 US disclosed
WO-2001058890-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2001-08-16 WO disclosed
EP-1067130-A1 TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT TORAY INDUSTRIES, INC. (JP) 2001-01-10 EP disclosed
WO-2000066591-A1 CYCLOCARBAMATE AND CYCLIC AMIDE DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO disclosed
US-4710506-A Antihypertensive thienopyridines THE BOOTS COMPANY PLC (GB) 1987-12-01 US disclosed
EP-0209977-A2 Thienopyridones, processes and intermediates for their preparation and pharmaceutical compositions containing them The Boots Company PLC (GB) 1987-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181962-A1 Substituted thiophene compounds ABCG2, SULT1E1, TPMT MAPT 2469/4885KDM4E 652/4885RAB9A 2237/4885
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 MAPT 2231/4885KDM4E 710/4885RAB9A 1568/4885
US-20020002173-A1 Cyclocarbamate and cyclic amide derivatives CNR1, PGR, NR5A1 MAPT 4814/4885KDM4E 3285/4885RAB9A 4234/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 MAPT 2231/4885KDM4E 710/4885RAB9A 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.